Research programme: DNA synthesis inhibitors - AdriacellAlternative Names: ADRIAC36; CROMOC
Latest Information Update: 16 Jul 2016
At a glance
- Originator Adriacell
- Class Proteins
- Mechanism of Action DNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Italy
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in Italy
- 20 Oct 2009 Early research in Inflammation in Italy (unspecified route)